NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Michael Weingarten, Director, NCI SBIR Development Center

Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute, one of 27 Institutes of the National Institutes of Health (NIH). In this role, Michael leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of over $115M in grants and contracts annually.

Under Michael's leadership, the NCI SBIR Development Center has launched a range of new programs to facilitate the success of small businesses in the cancer space. One of these new initiatives is a brand new funding program for the NIH known as the SBIR Phase II Bridge Award, which more than triples the amount of funding available to applicants through the NCI SBIR Program. NCI SBIR has also launched an investor forum where potential investors can get a first look at the most promising NCI SBIR companies developing the next generation of cancer therapeutic, diagnostic, or imaging technologies.

Prior to joining the NIH, Michael was the manager of partnership development activities for NASA's Technology Transfer program which included the SBIR program. He played a major role in the creation and design of NASA's Technology Transfer program – a network of 10 NASA research centers and six regional technology transfer centers. Michael has a bachelor's degree in political science from Northwestern University and a master's degree in political science from Columbia University.



Douglas Lowy, Deputy Director, NCI; Acting Director, Center for Strategic Scientific Initiatives (CSSI), NCI

Douglas Lowy is chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at the National Cancer Institute (NCI), National Institutes of Health. He is also a deputy director of the NCI, deputy director of the Center for Cancer Research, and acting director of CSSI at NCI. He received his medical degree from New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale when Dr. Aaron Lerner was the head of the department.

Doug's research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. The papillomavirus research is carried out in close collaboration with John Schiller, with whom he has co-authored more than 100 papers over the past 25 years. In the 1980s, they studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. More recently, they have worked on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the two FDA-approved HPV vaccines. Doug's growth regulation research includes prior studies that established the importance of the ras gene family in cancer and the main mechanisms by which the NF1 tumor suppressor gene regulates normal cell growth. His growth regulation research is now focused primarily on the DLC family of tumor suppressor genes and their mechanism of action. As was true of Dr. Lerner, Doug is a member of the National Academy of Sciences (NAS). He is also a member of the Institute of Medicine of the NAS.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Doug Rand, Senior Policy Advisor, White House Office of Science & Technology Policy (OSTP), Executive Office of the President

Doug Rand is a Senior Policy Advisor at the White House Office of Science and Technology Policy, where his work focuses on the Startup America initiative and efforts to promote entrepreneurship across the country. Prior to working at the White House, Doug served as co-founder and CEO of the innovative publishing company Playscripts, Inc., as well as a co-founder of the review aggregator StageGrade.

He is a graduate of Yale Law School and the Yale School of Management, and received Master's and undergraduate degrees from Harvard, where he studied evolutionary biology. As a writer, Doug's plays have been performed worldwide, and he has published numerous articles covering subjects from theater to politics to insects.

Susan Anthony, Attorney, Global Intellectual Property Academy, Office of Policy and External Affairs, United States Patent and Trademark Office (USPTO)

Susan Anthony is an attorney in the Global Intellectual Property Academy (GIPA), in the Office of Policy and External Affairs (OPEA), United States Patent and Trademark Office (USPTO), Alexandria, Virginia. Susan handles policy matters relating to copyright, trademark, and domain name issues within the U.S. and internationally and has a broad range of experience and expertise in almost all facets of intellectual property protection and enforcement.

Within GIPA, and with colleague Scott Baldwin, Susan heads up the USPTO's educational outreach initiative for American Indians and Alaska Natives, focused on helping small businesses and student entrepreneurs to protect and enforce their intellectual property rights. She also is a member of the USPTO China Team and the USPTO Africa Team. Prior to joining the USPTO, Susan worked in the corporate and private law firm sectors. Susan is a graduate of The George Washington University National Law Center in Washington, DC, and a long-time resident of Arlington, Virginia.

Jeffrey Roche, Medical Officer, Division of Items and Devices, Coverage and Analysis Group, Centers for Medicare and Medicaid Services (CMS)

After completing residency training in Anatomic and Clinical Pathology, Jeff worked as a hospital-based general pathologist from 1980 to 1997. After additional training in public health, he worked for the State of Maryland's Center for Clinical Epidemiology as a medical epidemiologist until late 2007.

More recently, in the Coverage and Analysis Group within the Center for Clinical Standards and Quality, Jeff has worked as a member of CMS teams considering national coverage determinations on various topics.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Richard Ledwidge, Drug Reviewer, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration (CDER, FDA)

Dr. Richard Ledwidge received his Ph.D. in Biochemistry from the Albert Einstein College of Medicine where he worked on the enzymological and biochemical characterization of bacterial proteins. Dr Ledwidge's post-doctoral training was at the University of California at San Francisco and a short stint at the National Institute of Allergy and Infectious Diseases. Dr. Ledwidge joined the Office of Biotechnology Products at the FDA as a CMC product reviewer in 2008.

Nina Hunter, Biologist, Division of Immunology and Hematology, Office of In Vitro Diagnostics and Radiological Health (OIR), Center for Devices and Radiological Health, Food and Drug Administration (CDRH, FDA)

After completing a Bachelor of Arts degree at Bowdoin College in Biochemistry and English, Dr. Hunter spent two years at the National Institutes of Health as a Postbaccalaureate Intramural Research Training Award Fellow.

She then studied at Harvard Medical School where she received her Ph.D. in Genetics from the Biological and Biochemical Sciences Program. After continuing biomedical research as a Post-Doctoral Fellow at Harvard Medical School, Dr. Hunter joined the FDA's Center for Devices and Radiological Health in 2008 as a Scientific Reviewer in the Office of In Vitro Diagnostics and Radiological Health. Currently, Dr. Hunter is a reviewer in the Division of Immunology and Hematology Devices where her duties focus mainly around premarket clearance/approval of molecular-based devices, including companion diagnostics, and IDE reviews.

David Parkinson, Venture Partner, New Enterprise Associates, Inc. and Former CEO of Nodality

David R. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007-2012, Dr. Parkinson served as President and CEO of Nodality, a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making.

Until October 2007 Dr. Parkinson was Senior Vice President, Oncology Research and Development, at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously, Dr. Parkinson worked at Amgen and Novartis, and was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics. Prior to joining industry, Dr. Parkinson worked at the National Cancer Institute, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. Dr. Parkinson is a past Chairman of the FDA Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently serves on the Boards of the Ontario Institute for Cancer Research and the Multiple Myeloma Research Foundation, and is the Chairman of the AACR Finance Committee.

Dr. Parkinson received his medical degree from the University of Toronto. He completed a Hematology Fellowship at Royal Victoria Hospital at McGill University in Montreal and was a Research Fellow at the New England Medical Center at Tufts University in Boston. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Walter M. Capone, Chief Operating Officer, The Multiple Myeloma Research Foundation

As Chief Operating Officer, Walter Capone oversees the core business and research operations of the MMRF and MMRC. As part of the Executive Committee, Walter is responsible for developing, designing, and executing the innovative growth initiatives to accelerate new drug development and the scientific programs dedicated to overcoming myeloma.

The introduction of non-profit-organization-driven expanded access programs, the launch of a landmark personalized medicine program, and the establishment of a pre-competitive industry consortium to enable open access clinical and molecular 'big data' are among the initiatives Walter has overseen since joining the MMRF two years ago.

Walter has over 20 years of pharmaceutical and biotechnology leadership experience in the areas of Commercial Development, Operations, Finance, Marketing, and Sales in the United States and internationally. Prior to joining the MMRF, he was the Vice President of Commercial Development and Operations at Progenics Pharmaceuticals focusing on the infectious disease, oncology, and immunology therapeutic areas. He previously worked at a number of entrepreneurial pharmaceutical and biotechnology ventures throughout the United States and Europe including Trimeris, Triangle Pharmaceuticals, and Cyanamid Benelux. He started his career at leading global pharmaceutical companies including Lederle, Wyeth, and Bristol-Myers Squibb. He received his BA in International Relations from Brown University and he has an MBA in Finance and International Business from Columbia University Business School.

Luis Carbonell, CEO, MagArray

Luis Carbonell is the CEO of MagArray, a startup company spun out of Stanford University that has developed a novel magnetic nanoparticle immunoassay technology. Prior to joining MagArray in 2010, he served for eight years as Vice President, Strategic Operations at Oncotech, a CLIA laboratory specializing in drug resistance testing for cancer patients.

Before Oncotech, Mr. Carbonell worked for Eisai, a Japanese-based global pharmaceutical company, where, from his base in Japan, he was responsible for the planning and establishment of new wholly-owned pharmaceutical research, manufacturing, and sales and marketing subsidiaries in the United States and China. His significant international experience also includes stints in various European countries and Southeast Asia. He received an MBA and a Master in Engineering Management degree from Northwestern University, and a Bachelor's degree in Mechanical Engineering from Stanford University.



Stephen Cary, CEO and Co-Founder, Omniox

Stephen Cary, PhD is the CEO and co-founder of Omniox, Inc., a biotechnology company commercializing a breakthrough oxygen delivery protein technology to address diseases of peripheral hypoxia such as chemo-radiation resistant cancers. Before founding Omniox, Dr. Cary spent three years in Development and Market Strategy at Genentech (now Roche).

He participated extensively in early stage development projects, and concentrated on the strategic process of transitioning therapeutic candidates from late-stage research to early development. Dr. Cary did his post-doctoral research in Immunology at Genentech. He was awarded three Genentech Excellence Awards for his work. Dr. Cary completed his PhD in Biological Chemistry at the University of Michigan and his Bachelor's degree in Biochemistry and Biophysics at Yale University.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Alex DeWinter, Director, Healthymagination Fund, GE Ventures

Alex DeWinter is a director at GE Ventures, in the Healthymagination Fund, where he invests in life science tools, clinical diagnostics, and big data related to healthcare. Prior to GE, Alex was a partner at Mohr Davidow Ventures. At Mohr Davidow, Alex was a board director at On-Q-ity, as well as a board observer for CardioDx, Corventis, Crescendo Bioscience, didimi, DVS Sciences, and Personalis.

He started his career as a research scientist with 454 Life Sciences and Pacific Biosciences. Alex has an MBA from UC Berkeley, a Ph.D. in chemistry from Stanford, and graduated magna cum laude from Amherst College.

Robin Jackman, Former President and CEO, Zacharon Pharmaceuticals (now BioMarin)

Robin Jackman is a biopharmaceutical executive with 20 years experience at the intersection of medicine, science, business, and finance. He has led or participated in over 90 life science partnership, financing, and M&A transactions collectively valued at over $11 billion. Most recently at Zacharon Pharmaceuticals, as CEO, he successfully led the venture-backed startup from financing through new orphan drug program development, multiple new partnerships, and on to a sale to BioMarin Pharmaceuticals in 2013.

Previously Dr. Jackman was with Vical where he ran the oncology division, which included completing a first-in-human exploratory phase 1 clinical study, as well as launching and enrolling a Phase 3 worldwide registration clinical trial encompassing over 120 clinical sites in 15 countries. Early in his career, he was an investment banker with the life-science unit at BankAmerica Robertson Stephens where he provided strategic and financing services to companies ranging from small venture-backed startups to large multinational pharmaceuticals. Robin holds graduate degrees from Harvard Medical School and Harvard University, and an undergraduate degree from Stanford University.

Michael Rubin, Managing Partner and Co-Founder, Sands Capital Ventures

Michael Rubin, MD, CFA, is the Managing Partner and co-founder of Sands Capital Ventures, and a partner at Sands Capital Management. Dr. Rubin has expertise in the life sciences and technology investments as an angel, venture, private equity, and public equity investor. Dr. Rubin has significant experience as a director and advisor to privately held businesses across multiple industries and stages.

Dr. Rubin became a board certified and licensed ophthalmologist and completed post-graduate retina fellowship training at Harvard Medical School, The Massachusetts General Hospital, and The Massachusetts Eye and Ear Infirmary. Dr. Rubin conducted molecular genetics research at Harvard's Ocular Molecular Genetics Institute, has written book chapters in leading texts, published in peer review journals, presented studies at international research forums, has led multiple research groups, and participated in large industry sponsored clinical trials. Dr. Rubin is a graduate of The University of Chicago Pritzker School of Medicine, received his MBA from the University of Massachusetts Amherst, and a BS in electrical engineering from UCLA. Dr. Rubin has received numerous awards including the Beem-Fisher Award and the Albert Potts Award for excellence in research, Harvard Medical School teaching award, and was elected as a fellow of the American Academy of Ophthalmology and as a member of the American College of Surgeons, alongside numerous honor societies.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Matt Portnoy, NIH SBIR Program Coordinator

Dr. Matthew Portnoy is the NIH SBIR/STTR Program Coordinator and Director, Division of Special Programs, Office of Extramural Programs, Office of Extramural Research, NIH. In this role, he manages the SBIR/STTR programs at NIH and coordinates the 24 NIH Institutes/Centers that receive funding for the programs. Matt received his BS in molecular and cell biology from Penn State University. He received his PhD in biochemistry and molecular biology from Johns Hopkins University School of Public Health.

Matt then joined the Intramural Program of National Human Genome Research Institute as a post-doctoral fellow. Dr. Portnoy made the leap to the extramural side of NIH in 2005 and joined the National Institute of General Medical Sciences as a program director. Over his time at NIGMS, he managed R01 grant portfolios in DNA repair, recombination and replication, SBIR/STTR grants, F32 post-doctoral fellowships, cooperative agreements, and R25 education grants. Dr. Portnoy also served as SBIR/STTR program lead for NIGMS for nearly 6 years prior to his current post.

Marcy Grace, Project Officer, Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS)

Dr. Marcy Beth Grace joined HHS in July 2008 as a Project Officer in Biodosimetry within the Biomedical Advancement Research and Development Authority (BARDA). Dr. Grace is currently a Project Officer in Chemical, Radiological, and Nuclear (CRN) Medical Countermeasures within the Division of CBRN Countermeasures. Dr. Grace serves as a subject matter expert on several Requirements Working Groups and Integrated Program Teams at BARDA.

Prior to coming to BARDA, Dr. Grace held positions as a Principal Investigator Research Biologist for the Armed Forces Radiobiology Research Institute (AFRRI) and held a Faculty Appointment as an Assistant Professor of Radiobiology in the School of Medicine at the Uniformed Services University of Health Sciences, Bethesda, Maryland. Dr. Grace earned a Ph.D. in Genetics from George Washington University. Dr. Grace's research at AFRRI received a Radiation Combined Injury Award from National Institutes of Health/National Institute of Allergy and Infectious Diseases for her studies of potential medical countermeasure agents in animal models. This research involved biodosimetry assay development for military use, and included rapid, noninvasive techniques that use peripheral whole blood samples. Potential biomarkers of interest for biodosimetry applications studied in her laboratory integrated radiation-responsive DNA damage biomarkers such as gamma H2AX, microRNAs, and gene expression changes in human models and in animal models.

Donna Kimbark, Program Manager, Peer Reviewed Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP), Department of Defense

Dr. Kimbark received her PhD in molecular pharmacology and cancer therapeutics from the State University of New York at Buffalo, Roswell Park Cancer Division. In 2005, she received a certificate in Epidemiology and Biostatistics from Drexel University. Following postdoctoral training at Johns Hopkins University, Dr. Kimbark worked in the biotechnology sector before joining the Congressionally Directed Medical Research Programs (CDMRP) in 2002 as Science Officer for the Breast Cancer Research Program.

Currently, Dr Kimbark is the Program Manager for multiple research programs at the CDMRP including; the Autism Research Program, the Bone Marrow Failure Research Program, the Multiple Sclerosis Research Program, and the Peer Reviewed Cancer Research Program. Her areas of expertise include cancer therapeutics, pharmacology, proteomics, and scientific research administration.

Jesus Soriano, Program Director, National Science Foundation (NSF)

Jesus Soriano joined the NSF in February 2012 as a Program Director in Biological and Chemical Technologies, after 20 years of international experience in executive leadership in the biopharmaceutical and non-profit sectors, start-up formation and funding, technology commercialization, and academic teaching and research. Prior to NSF, he was the Senior Advisor to the Puerto Rico Trust for Science, Technology and Research, a technology-based development organization.

He has also served as Senior Director of Business Development at Osiris Therapeutics, Inc. During his tenure, Osiris formed a $1.4 billion partnership with Genzyme Corp. to commercialize Prochymal™ and Chondrogen™, two first-in-class, late-stage adult stem cell therapeutics; and divested to NuVasive, Inc. the first-to-market adult stem-cell orthopedic implant, Osteocel®, for $137 million. Jesus held several executive leadership positions at the global bioresource center ATCC, including Vice President for IP, Licensing and International Business Development, and was Associate Director for R&D Operations and Business Development at Entremed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer.

Jesus began his career as a family doctor in Spain; he worked for 9 years at the University of Geneva Medical School, Switzerland as a Research Scientist and then as Assistant Professor. He initially came to the US as a visiting scientist to the National Cancer Institute (NIH) under an advanced researcher fellowship from the Swiss National Science Foundation. He holds an MBA in Corporate Finance from the Johns Hopkins Carey Business School; a PhD in Medical Sciences from the University of Geneva, Switzerland; and an MD from the University of Alicante, Spain.

James Tricoli, Chief, Diagnostic Biomarkers and Technology Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis (DCTD), NCI

James V. Tricoli, PhD is currently Chief of the Diagnostic Biomarkers and Technology Branch of the Cancer Diagnosis Program, a contributing member of the Molecular Characterization and Clinical Assay Development Laboratory at the Frederick National Laboratory for Cancer Research, and Adjunct Professor at Hood College, Frederick, Maryland. Scientific expertise includes biochemistry, cancer genetics, molecular biology, molecular genetics, urological cancers, and colon cancer. Interests include diagnostic, prognostic, and predictive biomarkers in cancer, technologies that advance capabilities in these areas, adolescent and young adult cancers and rare cancers. Currently chairman of the Clinical Assay Development Program internal review committee, member of the NCI-MATCH trial and Exceptional Cases working groups, member of the NCI adolescent and young adult oncology (AYAO) group and chairman of the basic biology working group of the AYAO.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Michael Difilippantonio, Program Manager for Therapeutic and Diagnostic Initiatives, Division of Cancer Treatment and Diagnosis (DCTD), NCI

Dr. Difilippantonio received a BS in Molecular and Cellular Biology, and a Certificate in Cytogenetics from the University of Connecticut.

He subsequently worked as a Clinical Cytogenetic Technologist in the laboratory of Dr. David C. Ward at Yale University, acquiring proficiency in the emerging field of fluorescence in situ hybridization for gene mapping. He earned his Ph.D. in Genetics at Yale University studying V(D)J recombination under the mentorship of Dr. David G. Schatz. He then took a position at NIH as a post-doctoral fellow, and later as Staff Scientist, in the laboratory of Dr. Thomas Ried where he applied molecular cytogenetic techniques to the study of colorectal cancer, chromosome missegregation and the role of aberrant DNA damage repair in tumorigenesis. He accepted a position as Program Manager for Therapeutic and Diagnostic Initiatives within the NCI Division of Cancer Treatment and Diagnosis (DCTD) in 2010. His responsibilities have included managing space for the Division, involvement in implementation of the NCI Experimental Therapeutics (NExT) Program and Functional Biology Consortium (FBC), and serving as Project Lead for several NExT/FBC projects. In addition, he serves as the Division representative on the NCI Health and Safety Committee, the NCI Risk Management Council, and the NCI Student Loan Repayment Program (SLRP) Committee.

Lili Portilla, Acting Director, NCATS Office of Policy, Communications, and Strategic Alliances

Ms. Portilla has worked in the area of technology transfer at the National Institutes of Health since 1989. She has extensive experience in negotiating and developing commercialization strategies for complex and multi-party collaborations and public private partnerships.

Ms. Portilla has broad knowledge of Federal and NIH technology transfer policy and law pertaining to biotechnology and commercialization issues. Ms. Portilla was recently named the Acting Director of the Office of Policy, Communications and Strategic Alliances at the newly formed National Center for Advancing Translational Sciences (NCATS) at the NIH. She currently serves as the Director of the Office of Strategic Alliances for NCATS.

Ms. Portilla currently serves as technology transfer advisor for the National Center for Research Resources (NCRR) funded Mutant Mouse Regional Resource Consortium and the National Swine Research Resource Center programs. Until recently Ms. Portilla served as the Chair of the Clinical Translational Science Awards (CTSA) Public Private Partnership Committee. Prior to her position at the NCRR, Ms. Portilla served for 7 years as the Director of the National Heart, Lung and Blood Institute (NHLBI), Office of Technology Transfer and Development (OTTAD). Ms. Portilla has published several papers on pubic private partnerships.

Ms. Portilla received a Masters in Public Administration in 1992 from American University, Washington, DC and a Bachelor in Business Administration, double major in both Finance and Spanish Literature in 1986 from Stephen F. Austin State University, Texas.

NCI SBIR Workshop on Federal Resources to Accelerate Commercialization
Speakers
May 7, 2013
8:00am – 5:30pm (EDT)

Vernon Steele, Acting Chief, Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NCI

Dr. Vernon Steele is a Program Director and Group Leader for the Chemoprevention Agent Development Research Group in the Division of Cancer Prevention, NCI. He earned his MS and PhD degree in Radiation Biology at The University of Rochester in 1975, studying radiation effects on cell differentiation, and recently received his Masters of Public Health degree from Johns Hopkins University, focusing on environmental toxicology.

Dr. Steele was an NCI Postdoctoral Fellow at Oak Ridge National Lab, then a Staff Fellow for 5 years at NIEHS in the area of pulmonary carcinogenesis and toxicology. He then moved to an environmental research company in Research Triangle Park, NC where he worked for the NIEHS, EPA, DOD and NCI on a broad range of research projects, including teratology, genetic and pulmonary toxicology, and cancer chemoprevention. Since joining NCI in 1989, he has been a Program Director for in vitro and in vivo screening, animal efficacy, and intermediate biomarker programs for identifying and developing new chemoprevention agents and investigating mechanisms in a variety of experimental cell and animal model systems. He is the author of over 250 peer-reviewed scientific journal papers, 21 book chapters, and has edited 2 books and 2 journal supplements.

Atsuo Kuki, Chief Technology Officer, SAIC-Frederick, Frederick National Laboratory for Cancer Research

Dr. Kuki is a life sciences executive and R&D leader at the Frederick National Laboratory for Cancer Research. He has led life sciences technology teams since 1986 in an evolving spectrum from experimental and theoretical protein biophysics, laser spectroscopy, parallel chemistry, computational physics, biotech drug discovery technologies, oncology pathway biology, and then global pharma Research management.

Dr. Kuki earned his BS in chemistry at Yale University and his PhD in experimental physical and biophysical chemistry at Stanford. He completed his postdoctoral studies in theoretical chemical physics at the University of Illinois before joining the faculty of Cornell University to work in biophysics and biophysical chemistry. In 1995, he became co-leader of a biotech drug discovery enterprise in La Jolla, subsequently acquired by Pfizer. While working at Pfizer La Jolla, Dr. Kuki held positions of increasing responsibility, culminating in his role as Executive Director of discovery technology. Dr. Kuki joined SAIC-Frederick in 2012 as Chief Technology Officer, where he leads 5 directorates that span the breadth of life science disciplines and advanced technology at the Frederick National Laboratory.